Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up.
In recent years, there has been a resurgence of interest in interstitial radiation as a cost-effective and efficient method of treating organ-confined prostate cancer. We describe our 7- and 8-year results with transperineal Iodine-125 and Palladium-103 implantation. A total of 551 consecutive patients were treated. Of these, 320/551 (58%) received implant alone (Group I), and 231/551 (42%)--considered higher risk patients--were also treated with a modest dose (45 Gy) of external beam irradiation (Group II). The median follow-up for Group I was 55 months, and for Group II, 60 months. At 7 years, the actuarial freedom from biochemical failure (prostate-specific antigen (PSA) < or = 1.0 ng/mL) was 80% in Group I patients, and, at 8 years, 65% in Group II patients. Morbidity was minimal if patients had not undergone prior transurethral prostate resections. The results indicate that interstitial radiation is a valid treatment for clinically localized prostate cancer.
Ragde
H
H
Northwest Hospital, Seattle, Washington, USA.
Blasko
J C
JC
Grimm
P D
PD
Kenny
G M
GM
Sylvester
J
J
Hoak
D C
DC
Cavanagh
W
W
Landin
K
K
D000206:Actuarial Analysis; D000230:Adenocarcinoma / Q000401:mortality / Q000532:radiotherapy*; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D001918:Brachytherapy; D016022:Case-Control Studies; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D009017:Morbidity; D010165:Palladium / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use; D011882:Radiotherapy, High-Energy; D013997:Time Factors
D014408:Biomarkers, Tumor; D007457:Iodine Radioisotopes; D011868:Radioisotopes; D010165:Palladium; D017430:Prostate-Specific Antigen